Candel 制药
CADL
8.19
-0.72
-8.08%
Candel 制药
US · CADL
#3461 按市值排名
上市于 2021
8.19
-0.72
-8.08%
实时 - 追踪5344个代码 - 心跳于32秒前
· 2026-10-16 19:52
✦ 量化股权信号 计算方式说明
减持
- 机构持股总比例下降了0.3个百分点。
机构持股
- 机构持股比例
- 73.76% -0.28pp
- 机构数量
- 165
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund39.24%
Hedge Fund20.64%
Individual/Insider7.57%
VC/PE Fund6.81%
Private Company5.78%
Public Company1.07%
Insurance Company0.18%
Other18.67%
主要股东 截至 2026-06-30
FMR
14.36% · 10.99M 股
RTW Investments, LP
8.39% · 6.42M 股
BlackRock
6.49% · 4.97M 股
Paul Manning
5.81% · 4.44M 股
State Street Global Advisors
4.64% · 3.55M 股
Acorn Bioventures
4.57% · 3.50M 股
Portolan Capital Management, LLC
4.56% · 3.49M 股
Saturn V Capital Management LP
4.32% · 3.30M 股
Vanguard Capital Management, LLC
4.06% · 3.11M 股
Estuardo Aguilar-Cordova 2020 Irrevocable Trust
2.71% · 2.07M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 43次买入 · 7次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Paul Manning | Independent Chairperson | 5.81% |
| Christopher Martell | Independent Director | 0.97% |
| Estuardo Aguilar-Cordova | Founder | 0.16% |
| Paul-Peter Tak | Chief Executive Officer | 0.15% |
| Joseph Papa | Independent Director | 0.13% |
| Francesca Barone | Chief Scientific Officer | 0.10% |
| Seshu Tyagarajan | Chief Technical & Development Officer | 0.10% |
| William Garrett | Chief Medical Officer | 0.07% |
| Charles Schoch | Interim CFO, Principal Financial & Principal Accounting Officer | 0.06% |
| Diem Nguyen | Independent Director | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Joseph Papa | Independent Director | Other Derivative Acquisition | +1,325 | $10.44 |
| 2026-09-29 | Paul Manning | Independent Chairperson | Other Derivative Acquisition | +2,189 | $10.44 |
| 2026-09-29 | Nicoletta Loggia | Independent Director | Other Derivative Acquisition | +380 | $10.44 |
| 2026-09-10 | Paul-Peter Tak | Chief Executive Officer | Automatic Disposition | -155,245 | $10.46–11.50 |
| 2026-09-09 | Paul-Peter Tak | Chief Executive Officer | Derivative Exercise and Sale | -125,000 | $1.55–11.50 |
| 2026-09-07 | Martine Zimmermann | Independent Director | Other Derivative Acquisition | +64,000 | $12.60 |
| 2026-08-16 | Seshu Tyagarajan | Chief Technical & Development Officer | Automatic Disposition | -7,000 | $12.00 |
| 2026-06-29 | Joseph Papa | Independent Director | Other Derivative Acquisition | +1,331 | $10.30 |
| 2026-06-29 | Paul Manning | Independent Chairperson | Other Derivative Acquisition | +2,199 | $10.30 |
| 2026-06-29 | Nicoletta Loggia | Independent Director | Other Derivative Acquisition | +381 | $10.30 |
| 2026-06-28 | Francesca Barone | Chief Scientific Officer | Automatic Disposition | -23,447 | $10.06 |
| 2026-06-28 | Seshu Tyagarajan | Chief Technical & Development Officer | Automatic Disposition | -7,000 | $10.02 |
| 2026-06-22 | Joseph Papa | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Edward Benz | Member of Research Advisory Board & Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Paul Manning | Independent Chairperson | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Gary Nabel | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Renee Gaeta | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Mahalakshmi Radhakrishnan | Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Christopher Martell | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Diem Nguyen | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:52:44 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
Candel 制药 讨论区 0 条评论